- Home
- SFWL vs ADAP Comparison
SFWL vs ADAP Comparison
Compare SFWL & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- ADAP
- Stock Information
- Founded
- SFWL 2001
- ADAP 2008
- Country
- SFWL China
- ADAP United Kingdom
- Employees
- SFWL N/A
- ADAP N/A
- Industry
- SFWL Trucking Freight/Courier Services
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- ADAP Health Care
- Exchange
- SFWL Nasdaq
- ADAP Nasdaq
- Market Cap
- SFWL 74.2M
- ADAP 75.5M
- IPO Year
- SFWL 2023
- ADAP 2015
- Fundamental
- Price
- SFWL $1.02
- ADAP $0.29
- Analyst Decision
- SFWL
- ADAP Buy
- Analyst Count
- SFWL 0
- ADAP 6
- Target Price
- SFWL N/A
- ADAP $1.52
- AVG Volume (30 Days)
- SFWL 10.3K
- ADAP 1.6M
- Earning Date
- SFWL 06-10-2025
- ADAP 05-13-2025
- Dividend Yield
- SFWL N/A
- ADAP N/A
- EPS Growth
- SFWL 4.79
- ADAP N/A
- EPS
- SFWL 0.13
- ADAP N/A
- Revenue
- SFWL $504,158,000.00
- ADAP $179,639,000.00
- Revenue This Year
- SFWL N/A
- ADAP N/A
- Revenue Next Year
- SFWL N/A
- ADAP $52.49
- P/E Ratio
- SFWL $7.72
- ADAP N/A
- Revenue Growth
- SFWL 24.75
- ADAP 878.53
- 52 Week Low
- SFWL $0.81
- ADAP $0.20
- 52 Week High
- SFWL $2.15
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- SFWL 54.75
- ADAP 53.94
- Support Level
- SFWL $0.94
- ADAP $0.26
- Resistance Level
- SFWL $1.02
- ADAP $0.30
- Average True Range (ATR)
- SFWL 0.05
- ADAP 0.03
- MACD
- SFWL -0.00
- ADAP 0.00
- Stochastic Oscillator
- SFWL 68.67
- ADAP 58.12
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.